Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9005)
All Articles published online
|
Publishing Process of This Article
|
Feb 10, 2017 (publication date) through Nov 21, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bersanelli M, Buti S. From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin Oncol 2017; 8(1): 37-53 [PMID: 28246584 DOI: 10.5306/wjco.v8.i1.37] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v8/i1/37.htm |
| Number | Citing Articles |
| 1 |
A. Filippone, M. Lanza, D. Mannino, G. Raciti, C. Colarossi, D. Sciacca, S. Cuzzocrea, I. Paterniti. PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression. Cancer Immunology, Immunotherapy 2022; 71(9): 2067 doi: 10.1007/s00262-021-03130-z
|
| 2 |
Chunbao Chen, Xue Du, Hongjun Liu, Xingyu Lu, Dong Li, Jian Qi. Construction of a prognostic classifier and prediction of the immune landscape and immunosuppressive molecules in gliomas based on combination of inflammatory response-related genes and angiogenesis-associated genes. European Journal of Inflammation 2022; 20 doi: 10.1177/1721727X221133708
|
| 3 |
Melissa Bersanelli, Alessio Cortellini, Sebastiano Buti. The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the “inflamed tumor” to the “inflamed patient”. Human Vaccines & Immunotherapeutics 2021; 17(7): 1930 doi: 10.1080/21645515.2020.1852872
|
| 4 |
Xiaojun Shi, Xinji Zhang, Jinlong Li, Hongfan Zhao, Lijun Mo, Xianghua Shi, Zhiming Hu, Jimin Gao, Wanlong Tan. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer. Cancer Letters 2017; 406: 27 doi: 10.1016/j.canlet.2017.07.029
|
| 5 |
Weiwei Zhao, Falin Zhao, Kai Yang, Yaxin Lu, Yuanyuan Zhang, Wenjie Wang, Hongyu Xie, Kui Deng, Chunyan Yang, Zhiwei Rong, Yan Hou, Kang Li. An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade. Journal of Cellular Biochemistry 2019; 120(8): 13330 doi: 10.1002/jcb.28607
|
| 6 |
K. White, K. Connor, J. Clerkin, B.M. Murphy, M. Salvucci, A.C. O'Farrell, M. Rehm, D. O'Brien, J.H.M. Prehn, S.P. Niclou, M.L.M. Lamfers, M. Verreault, A. Idbaih, R. Verhaak, A. Golebiewska, A.T. Byrne. New hints towards a precision medicine strategy for IDH wild-type glioblastoma. Annals of Oncology 2020; 31(12): 1679 doi: 10.1016/j.annonc.2020.08.2336
|
| 7 |
Qin Zhang, Chaowei Gao, Jianqiang Shao, Zunyi Wang. TIGIT-related transcriptome profile and its association with tumor immune microenvironment in breast cancer. Bioscience Reports 2021; 41(3) doi: 10.1042/BSR20204340
|
| 8 |
Yi-bo He, Lu-wei Fang, Dan Hu, Shi-liang Chen, Si-yu Shen, Kai-li Chen, Jie Mu, Jun-yu Li, Hongpan Zhang, Liu Yong-lin, Li Zhang. Necroptosis-associated long noncoding RNAs can predict prognosis and differentiate between cold and hot tumors in ovarian cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.967207
|
| 9 |
Stine Asferg Petterson, Mia Dahl Sørensen, Mark Burton, Mads Thomassen, Torben A. Kruse, Signe Regner Michaelsen, Bjarne Winther Kristensen. Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas. Brain Pathology 2023; 33(1) doi: 10.1111/bpa.13111
|
| 10 |
Enrica Capelletto, Silvia Novello. Practical Medical Oncology Textbook. UNIPA Springer Series 2021; : 517 doi: 10.1007/978-3-030-56051-5_33
|
| 11 |
Claire Vanpouille-Box, Claire Lhuillier, Lucillia Bezu, Fernando Aranda, Takahiro Yamazaki, Oliver Kepp, Jitka Fucikova, Radek Spisek, Sandra Demaria, Silvia C. Formenti, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi. Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology 2017; 6(11): e1373237 doi: 10.1080/2162402X.2017.1373237
|
| 12 |
Sumeet Hindocha, Des Campbell, Merina Ahmed, Kyriaki Giorgakoudi, Bhupinder Sharma, Nadia Yousaf, Philip Molyneaux, Benjamin Hunter, Hardeep Kalsi, Wanyuan Cui, Michael Davidson, Jaishree Bhosle, Anna Minchom, Imogen Locke, Fiona McDonald, Mary O'Brien, Sanjay Popat, Richard W. Lee. Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.764563
|
| 13 |
Parisa Badiee, Michelle F Maritz, Benjamin Thierry. Glycogen kinase 3 inhibitor nanoformulation as an alternative strategy to inhibit PD-1 immune checkpoint. International Journal of Pharmaceutics 2022; 622: 121845 doi: 10.1016/j.ijpharm.2022.121845
|
| 14 |
Mridula Krishnan, Pooja Kasinath, Robin High, Fang Yu, Benjamin A. Teply. Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors. JCO Oncology Practice 2022; 18(1): e175 doi: 10.1200/OP.20.01055
|
| 15 |
Melissa Bersanelli, Sebastiano Buti, Ugo De Giorgi, Massimo Di Maio, Diana Giannarelli, Sandro Pignata, Giuseppe Luigi Banna. State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough. Critical Reviews in Oncology/Hematology 2019; 139: 87 doi: 10.1016/j.critrevonc.2019.05.003
|
| 16 |
Meltiady Issa, Ioannis Milioglou. Unusual case of immune-related colitis. BMJ Case Reports 2017; : bcr-2017-221319 doi: 10.1136/bcr-2017-221319
|
| 17 |
Cecilia Olsson Ladjevardi, Marcus Skribek, Anthoula Koliadi, Viktoria Rydén, Ali Inan El-Naggar, Evangelos Digkas, Antonios Valachis, Gustav J. Ullenhag. Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer. Cancer Immunology, Immunotherapy 2024; 74(1) doi: 10.1007/s00262-024-03869-1
|
| 18 |
Sumeet Hindocha, Benjamin Hunter, Kristofer Linton-Reid, Thomas George Charlton, Mitchell Chen, Andrew Logan, Merina Ahmed, Imogen Locke, Bhupinder Sharma, Simon Doran, Matthew Orton, Catey Bunce, Danielle Power, Shahreen Ahmad, Karen Chan, Peng Ng, Richard Toshner, Binnaz Yasar, John Conibear, Ravindhi Murphy, Tom Newsom-Davis, Patrick Goodley, Matthew Evison, Nadia Yousaf, George Bitar, Fiona McDonald, Matthew Blackledge, Eric Aboagye, Richard Lee. Validated machine learning tools to distinguish immune checkpoint inhibitor, radiotherapy, COVID-19 and other infective pneumonitis. Radiotherapy and Oncology 2024; 195: 110266 doi: 10.1016/j.radonc.2024.110266
|
| 19 |
雨生 张. The Expression of CD155 on Renal Cell Carcinoma Cells. Advances in Clinical Medicine 2019; 9(03): 373 doi: 10.12677/ACM.2019.93057
|
| 20 |
Melissa Bersanelli, Letizia Gnetti, Francesco Paolo Pilato, Elena Varotti, Federico Quaini, Nicoletta Campanini, Elena Rapacchi, Roberta Camisa, Paolo Carbognani, Enrico Maria Silini, Michele Rusca, Francesco Leonardi, Umberto Maestroni, Mimma Rizzo, Matteo Brunelli, Sebastiano Buti, Luca Ampollini. Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity. Exploration of Targeted Anti-tumor Therapy 2023; : 743 doi: 10.37349/etat.2023.00165
|
| 21 |
Melissa Bersanelli, Diana Giannarelli, Paola Castrignanò, Giuseppe Fornarini, Stefano Panni, Francesca Mazzoni, Marcello Tiseo, Sabrina Rossetti, Elisabetta Gambale, Ernesto Rossi, Anselmo Papa, Alessio Cortellini, Cristian Lolli, Raffaele Ratta, Maria Michiara, Michele Milella, Emmanuele De Luca, Mariella Sorarù, Claudia Mucciarini, Francesco Atzori, Giuseppe Luigi Banna, Leonardo La Torre, Maria Giuseppa Vitale, Francesco Massari, Sara Elena Rebuzzi, Gaetano Facchini, Giovanni Schinzari, Silverio Tomao, Simona Bui, Vanja Vaccaro, Giuseppe Procopio, Ugo De Giorgi, Matteo Santoni, Corrado Ficorella, Roberto Sabbatini, Antonio Maestri, Clara Natoli, Michele De Tursi, Massimo Di Maio, Elena Rapacchi, Annagrazia Pireddu, Teodoro Sava, Helga Lipari, Francesca Comito, Elena Verzoni, Francesco Leonardi, Sebastiano Buti. Influenza Vaccine Indication During Therapy with Immune Checkpoint Inhibitors: A Transversal Challenge. The Invidia Study. Immunotherapy 2018; 10(14): 1229 doi: 10.2217/imt-2018-0080
|
| 22 |
Massimo Romani, Maria Pia Pistillo, Roberta Carosio, Anna Morabito, Barbara Banelli. Immune Checkpoints and Innovative Therapies in Glioblastoma. Frontiers in Oncology 2018; 8 doi: 10.3389/fonc.2018.00464
|
| 23 |
Marina Gergues, Vibha Harindra Savanur, David Prado, Adam Eljarrah, James K. Liu, Mohammed Jaloudi, Pranela Rameshwar. Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies. 2021; : 507 doi: 10.1016/B978-0-12-821567-8.00012-9
|
| 24 |
Melissa Bersanelli, Letizia Gnetti, Elena Varotti, Luca Ampollini, Paolo Carbognani, Francesco Leonardi, Michele Rusca, Nicoletta Campanini, Francesco Ziglioli, Clara I Dadomo, Francesco P Pilato, Alessio Cortellini, Elena Rapacchi, Giuseppe Caruso, Enrico M Silini, Umberto Maestroni, Sebastiano Buti. Immune Context Characterization and Heterogeneity in Primary Tumors and Pulmonary Metastases from Renal Cell Carcinoma. Immunotherapy 2019; 11(1): 21 doi: 10.2217/imt-2018-0097
|
| 25 |
Natalya Lisovska. Multilevel mechanism of immune checkpoint inhibitor action in solid tumors: History, present issues and future development (Review). Oncology Letters 2022; 23(6) doi: 10.3892/ol.2022.13310
|
| 26 |
Natalya Lisovska, Nasrulla Shanazarov. Tumor progression mechanisms: Insights from the central immune regulation of tissue homeostasis (Review). Oncology Letters 2019; doi: 10.3892/ol.2019.10218
|
| 27 |
Qiang Liu, Ran Cheng, Xiangyi Kong, Zhongzhao Wang, Yi Fang, Jing Wang. Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.558757
|
| 28 |
Francesco Facchinetti, Letizia Gnetti, Marcello Tiseo. The Mediastinal Mass. Current Clinical Pathology 2018; : 163 doi: 10.1007/978-3-319-90368-2_8
|
| 29 |
Xiaojun Shi, Xinji Zhang, Jinlong Li, Lijun Mo, Hongfan Zhao, Yongtong Zhu, Zhiming Hu, Jimin Gao, Wanlong Tan. PD‐1 blockade enhances the antitumor efficacy of GM‐CSF surface‐modified bladder cancer stem cells vaccine. International Journal of Cancer 2018; 142(10): 2106 doi: 10.1002/ijc.31219
|
| 30 |
Melissa Bersanelli, Matteo Brighenti, Sebastiano Buti, Sandro Barni, Fausto Petrelli. Patient performance status and cancer immunotherapy efficacy: a meta-analysis. Medical Oncology 2018; 35(10) doi: 10.1007/s12032-018-1194-4
|
| 31 |
Qin Zhang, Chaowei Gao, Jianqiang Shao, Shengze Zhang, Peng Wang, Zunyi Wang. Molecular and Clinical Characterization of CD80 Expression via Large-Scale Analysis in Breast Cancer. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.869877
|
| 32 |
Andreea Cătălina Tinca, Iuliu Gabriel Cocuz, Mihaela Cornelia Șincu, Raluca Niculescu, Adrian Horațiu Sabău, Diana Maria Chiorean, Andreea Raluca Szőke, Ovidiu Simion Cotoi. VISTA, PDL-L1, and BRAF—A Review of New and Old Markers in the Prognosis of Melanoma. Medicina 2022; 58(1): 74 doi: 10.3390/medicina58010074
|
| 33 |
Varsha Singh. Can Vitamins, as Epigenetic Modifiers, Enhance Immunity in COVID-19 Patients with Non-communicable Disease?. Current Nutrition Reports 2020; 9(3): 202 doi: 10.1007/s13668-020-00330-4
|
| 34 |
Guranda Chitadze, Hans-Heinrich Oberg, Daniela Wesch, Dieter Kabelitz. The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity. Trends in Immunology 2017; 38(9): 668 doi: 10.1016/j.it.2017.06.004
|
| 35 |
Chao-Jie Wang, Chun-Chao Zhu, Jia Xu, Ming Wang, Wen-Yi Zhao, Qiang Liu, Gang Zhao, Zi-Zhen Zhang. The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs. Molecular Cancer 2019; 18(1) doi: 10.1186/s12943-019-1032-0
|
| 36 |
Edina Gyukity-Sebestyén, Mária Harmati, Gabriella Dobra, István B. Németh, Johanna Mihály, Ágnes Zvara, Éva Hunyadi-Gulyás, Róbert Katona, István Nagy, Péter Horváth, Árpád Bálind, Ábel Szkalisity, Mária Kovács, Tibor Pankotai, Barbara Borsos, Miklós Erdélyi, Zsolt Szegletes, Zoltán J. Veréb, Edit I. Buzás, Lajos Kemény, Tamás Bíró, Krisztina Buzás. Melanoma-Derived Exosomes Induce PD-1 Overexpression and Tumor Progression via Mesenchymal Stem Cell Oncogenic Reprogramming. Frontiers in Immunology 2019; 10 doi: 10.3389/fimmu.2019.02459
|
| 37 |
Yongshuai Li, Jiaqiong Li, Huaqing Chen, Bo Lu, Fei Lu, Hairong Chen, Hongyi Liu, Chunfa Qian. TCAF2 is associated with the immune microenvironment, promotes pathogenesis, and impairs prognosis in glioma. Gene 2023; 883: 147667 doi: 10.1016/j.gene.2023.147667
|
| 38 |
Mohamed Rahouma, Nagla Abdel Karim, Massimo Baudo, Maha Yahia, Mohamed Kamel, Ihab Eldessouki, Ahmed Abouarab, Ihab Saad, Adham Elmously, Katherine D Gray, Galal Ghaly, Ola Gaber, Mona Kamal, Ayah A Hassan, Mostafa Rahouma, Fabrizio D’Ascenzo, John Morris, Abdelrahman Mohamed, Leonard Girardi, Mario Gaudino. Cardiotoxicity with Immune System Targeting Drugs: A Meta-Analysis of Anti-PD/PD-L1 Immunotherapy Randomized Clinical Trials. Immunotherapy 2019; 11(8): 725 doi: 10.2217/imt-2018-0118
|
| 39 |
Melissa Bersanelli, Alessandro Leonetti, Sebastiano Buti. The Link Between Calcitriol and Anticancer Immunotherapy: Vitamin D as the Possible Balance Between Inflammation and Autoimmunity in the Immune-Checkpoint Blockade. Immunotherapy 2017; 9(14): 1127 doi: 10.2217/imt-2017-0127
|
| 40 |
Jixing Zhao, Wu Yan, Wencong Huang, Yongsheng Li. Circ_0010235 facilitates lung cancer development and immune escape by regulating miR‐636/PDL1 axis. Thoracic Cancer 2022; 13(7): 965 doi: 10.1111/1759-7714.14338
|
| 41 |
Cecilia Olsson Ladjevardi, Anthoula Koliadi, Viktoria Rydén, Ali Inan El‐Naggar, Evangelos Digkas, Antonios Valachis, Gustav J. Ullenhag. Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study. Cancer Medicine 2023; 12(12): 13217 doi: 10.1002/cam4.6013
|
| 42 |
Bharati Mehani, Saleembhasha Asanigari, Hye-Jung Chung, Karen Dazelle, Arashdeep Singh, Sridhar Hannenhalli, Kenneth Aldape. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology. Acta Neuropathologica Communications 2022; 10(1) doi: 10.1186/s40478-022-01323-w
|
| 43 |
Na Zhang, Li Wei, Meng Ye, Chunsheng Kang, Hua You. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.592612
|
| 44 |
Melissa Bersanelli. Controversies About COVID-19 and Anticancer Treatment with Immune Checkpoint Inhibitors. Immunotherapy 2020; 12(5): 269 doi: 10.2217/imt-2020-0067
|
| 45 |
Melissa Bersanelli. COVID-19 and the Newly Rediscovered Multidisciplinarity. Immunotherapy 2020; 12(15): 1101 doi: 10.2217/imt-2020-0205
|
| 46 |
Melissa Bersanelli, Stefania Scala, Paola Affanni, Licia Veronesi, Maria Eugenia Colucci, Giuseppe Luigi Banna, Alessio Cortellini, Francesco Liotta. Immunological Insights on Influenza Infection and Vaccination During Immune Checkpoint Blockade In Cancer Patients. Immunotherapy 2020; 12(2): 105 doi: 10.2217/imt-2019-0200
|
| 47 |
Salvatore Trapani, Moana Manicone, Angelica Sikokis, Nunziata D’Abbiero, Francesco Salaroli, Giovanni Ceccon, Sebastiano Buti. Effectiveness and safety of “real” concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review. Critical Reviews in Oncology/Hematology 2019; 142: 9 doi: 10.1016/j.critrevonc.2019.07.006
|